🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢 Come hear Harvard Radiation Oncology Program resident Nayan Lamba, MD speak at ASCO this Sunday 6/5 about the genomics of brain metastases in the session chaired by Nancy Lin, MD and Rupesh Kotecha, "Are Big Data Smart Enough to Answer Questions in CNS Tumors?" at 10:30 AM! Q/A to follow! #ASCO2023

Rupesh Kotecha oral CNS track @asco use of novel PET tracer to distinguish b/w radiation necrosis & tumor progression post RT in brain metastases- a common clinical challenge. 80% sensitivity, 85 specificity! Novel modality in tool box! Miami Cancer Institute Research Manmeet Ahluwalia, MD, MBA, FASCO #ASCO2023

🔬 Today at the ASCO Annual Meeting 2023, where groundbreaking advancements in cancer research and treatment are taking center stage! 🎉 New on OncologyTube! 🎥 oncologytube.com/video/42011/18… The Power of 18F-Fluciclovine PET Dr. Rupesh Kotecha Miami Cancer Institute Research #BrainMetastases #ASCO23

Haley Appel, PA-C speaks on evaluating the diagnostic performance of #leptomeningeal diagnosis with CNSide™ compared to standard #cytology. #ASCO23 ASCO #BaptistHealthResearch

Our #MiamiCancerInstitute experts shared the latest #cancerresearch at ASCO 2023 this year. Presentations focused on brain #metastases, #bladdercancer, #lungcancer, #glioblastoma, and more. Check out some great footage of our experts in action! #ASCO23 #MedTwitter

MrBeast #pancreaticcancer is one of the deadliest cancers. We need funding for practice changing #clinicaltrials. Our ablative #MRIdian therapy data show incredible survival improvements even for very advanced tumors! Help us change the face of this disease! 🙏🙏 broadcastmed.com/cancer/1106/ne…

Work hard play hard! 😎💪 The Miami Cancer Institute Research team and Michael Vogelbaum enjoyed a productive day of meetings and then the #NRG2023 reception. I’m fortunate to work with this brilliant group everyday! 🤩🤩

How do we manage IDHm LGG post-INDIGO? · Multi-disciplinary decision-making mandatory · Vorasidenib active agent reasonable for intermediate risk patients · OS Impact Vorasidenib unknown (+ = or -) ascopubs.org/doi/10.1200/JC…

Congratulations to Dr. Rupesh Kotecha and our #RadOnc team at @miamicancerinst for the newly published study highlighting outcomes for patients with large brain metastasis treated with SRS, FSRS, and surgery in the Journal of Neuro-Oncology Journal of Neuro-Oncology ➡️ bapth.lt/3KxWwS7

Excited to be open to accrual! Lucky number NRG BN013 - a phase 3 randomized trial of SRS vs. FSRS for intact brain mets NRG Oncology @JYangMDPhD Martin Tom Manmeet Ahluwalia, MD, MBA, FASCO Michael Vogelbaum Mei Polley

The NRG-BN013 phase III clinical trial was recently activated as a part of the NRG Oncology brain tumor portfolio. NRG-BN013 will compare two schedules of stereotactic radiosurgery (SRS) for patients with intact brain metastases. Rupesh Kotecha Read more: ow.ly/7Paq50Tmfma

Rupesh Kotecha, MD, (Rupesh Kotecha) discussed a machine learning tool designed to predict local failure after stereotactic radiosurgery for brain metastases. #ASTRO24 | Miami Cancer Institute Research Baptist Health Cancer Care Baptist Health targetedonc.com/view/machine-l…

Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer. #lcsm | Rupesh Kotecha Miami Cancer Institute Research Baptist Health Cancer Care Baptist Health targetedonc.com/view/systemic-…

I was supposed to present a ph3 trial concept for medically inoperable but technically resectable stage I-II pancreatic cancer today to NCI pancreas task force. But that was cancelled while I was on the ✈️ to San Fran… 🤨 What % of upfront resectable PDAC have surgery?

Can’t wait to see wonderful colleagues and hear exciting talks from world-renowned experts at the Cleveland Clinic 17th Annual International Symposium on SBRT & SRS. Don’t miss this! There is still time to register: ccfcme.org/SBRT

🚀Ph2 SMART ONE trial in press 🔹1-fx SBRT on 0.35T MR-Linac 🔹2/3 targets abd/pelvis, 1/3 lung 🔹🔥🔥 plans!! Median GTV mean dose: adrenal 32.3 Gy, LN 31.7 Gy, liver 45.4 Gy, lung 42.8 Gy 🔹Median time 53 min, ART routine 🔹1-yr LC 96.2%, 1-yr OS 86.3% redjournal.org/article/S0360-…

📢Very proud of our recent publications from Miami Cancer Institute Research ...results of SMART ONE, proton RICE categorization, and SBRT for infra-diaphragmatic oligomets with MRgRT...something for everyone, check it out now online at IJROBP - The Red Journal! Michael Chuong

Thanks to QuadShot News for highlighting our analysis -138 pts w/ abd mets mostly LN, adrenal gland, liver -Most lung/GI primaries -SMART on 035.T MRL, med 50 Gy/5 fx -Online ART 77% of fx -GTV 95%=98.1 Gy BED10🔥 -2yr LC 84% -Acute/late gr3 tox 0%/2.2% redjournal.org/article/S0360-…

Pertinent ongoing trial NRG BN014 Proton CSI vs involved field RT for Breast CA or NSCLC LMD (RADIATE-LM) PI @JYangMDPhD William Breen Jona Hattangadi-Gluth, MD Rupesh Kotecha Manmeet Ahluwalia, MD, MBA, FASCO

May is #BrainCancerAwarenessMonth! We asked Rupesh Kotecha, NRG-BN013 Principal Investigator, to discuss this Phase III study of single fraction stereotactic radiosurgery (SRS) versus fractionated SRS (fSRS) for intact brain metastases youtube.com/watch?v=s-MWC4…